Tom 7, Nr 1 (2022)
List do Redakcji
Opublikowany online: 2021-12-13
Wyświetlenia strony
4997
Wyświetlenia/pobrania artykułu
133
Is the elimination of cervical cancer now 3 times easier? One-dose vaccine efficacy has far-reaching implications
1
, 2, 1
, 2, 1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(1):66-67.
Streszczenie
Brak
Referencje
- Kunitoki K, Funato M, Mitsunami M, et al. Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence. Vaccine. 2021; 39(41): 6104–6110.
- Karafillakis E, Simas C, Jarrett C, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019; 15(7-8): 1615–1627.
- Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021; 194: 245–251.
- Basu P, Malvi S, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. The Lancet Oncology. 2021; 22(11): 1518–1529.
- Garland SM, Stanley MA, Giuliano AR, et al. IPVS Policy Committee. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity". Papillomavirus Res. 2020; 9: 100195.
- Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016; 13(2): 119–132.
- Dillner J, Elfström KM, Baussano I. Prospects for accelerated elimination of cervical cancer. Prev Med. 2021; 153: 106827.
